Study #2022-0005
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
MD Anderson Study Status
Not Accepting
Treatment Agent
Rusfertide, Placebo
Description
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Polycythemia Vera
Study phase:
Phase III
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-833-802-0471
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.